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ABSTRACT
Vaccines designed to abrogate the tolerance of tumor self-antigens and amplify cytotoxic CD8C T cells
(CTLs) have promise for the treatment of cancer. Type I natural killer (NKT) cells have attracted
considerable interest in the cancer therapy field. In the current study, we have exploited the unique ability
of NKT cells to serve as T-helper cells to license dendritic cells (DCs) for cross priming with the aim to
generate efficient CTL antitumor responses. To this end, we designed a nanoparticle-based vaccine to
target cross-priming DCs via the Clec9a endocytic pathway. Our results showed for the first time that
simultaneous co-delivery of the NKT agonist a-galactosylceramide and tumor self-antigens (Trp2 and
gp100) to CD8aC DCs promotes strong antitumor responses in prophylactic and therapeutic settings
(advanced solid tumor model in the mouse). We attributed the vaccine’s therapeutic effects to NKT cells
(but not to T-helper lymphocytes) and CD8C T cells. Efficacy was correlated with an elevated ratio
between tumor antigen-specific CD8C T cells and regulatory CD4C T lymphocytes within the tumor. The
nanoparticle-based vaccine actively targeted human CLEC9A-expressing BDCA3C DCs - the equivalent of
murine cross-priming CD8aC DCs - and induced a strong expansion of effector memory tumor self-
antigen (Melan -A)-specific CD8C T cells from peripheral blood mononuclear cells sourced from healthy
donors and melanoma patients. Together, our result shed light on novel therapeutic approaches for
controlling tumor development.
Abbreviations: CTLs, cytotoxic CD8C T cells; DCs, dendritic cells; TLR, Toll-like receptors; NKT cells, natural killer T
cells; OVA, ovalbumin; NP, nanoparticle; Abs, antibodies; PBMC, peripheral blood mononuclear cells; PD1,
programmed cell death protein-1; LN, lymph node; PLGA, Poly(lactic-co-glycolic acid)
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Introduction
Although vaccines designed to promote the development of
tumor-specific cytotoxic CD8C T cells (CTLs) have promise for
cancer treatment, optimization (to abrogate the tolerance of
tumor self-antigens) is urgently needed (for reviews,.1-3 The
development of effective CTLs implies the adequate stimulation
of naive CD8C T cells by dendritic cells (DCs). A variety of fac-
tors influence the strength and quality of the CTL response,
including the nature of the DC subset, the duration of antigen
presentation, and the type of costimulatory signals received by
the naive CD8C T cells.1,3 The BDCA3C DC subset (in humans)
and the CD8aC DC subset (in the mouse) excel in antigen
cross-presentation and the priming of CD8C T cells.4-6 Many
research groups have reported that tumor antigen presentation
by cross-priming DCs is essential for an effective antitumor
CTL response.1,3 This unique property is currently used to
enhance the efficacy of tumor vaccines whose delivery systems
target cross-priming DCs7-10; this approach is now in clinical
development.11 Activating/licensing signals are required for the
effective induction of CTL responses, and co-stimulatory sig-
nals delivered by DC-expressed pattern recognition receptors
and/or T-helper cells are critical in this respect.3,12,13 Many
attempts have been made to optimize the CTL response in
tumor settings by using various classes of Toll-like receptor
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(TLR) agonist.14,15 Other studies have demonstrated the value
of delivering both CTL and T-helper epitopes to the same DC
and thus favoring DC/T-helper cell/naive CD8C T cell encoun-
ters - the so called “menage a trois”.16,17 In the present study,
we chose an alternative strategy based on the recruitment of
another type of helper cell for cross-priming DCs - namely
type I natural killer T (NKT) cells.
type I NKT cells belong to the “innate-like” T lymphocyte
family. Through a semi-invariant T cell receptor, these non-
conventional T cells recognize lipid antigens presented by the
monomorphic CD1d molecule on antigen-presenting cells,
including DCs.18-20 In response to the superagonist a-galacto-
sylceramide (a-GalCer), NKT cells swiftly produce immunosti-
mulatory cytokines (including large amounts of IFN-g) and
up-regulate several costimulatory molecules (e.g. CD40); this
leads to DC maturation and the downstream activation of criti-
cal effectors of antitumor immunity, including NK cells and T
lymphocytes.21-23 Importantly, Semmling et al. elegantly dem-
onstrated that NKT cells can license DCs for cross-priming
through a mechanism other than that used by T-helper cells.24
This alternative cross-priming may lead to a CTL response that
differs from classical cross-priming. We noted that Semmling
et al. studied the model antigen ovalbumin (OVA), rather than
a self-antigen. This observation prompted us to try to co-deliver
tumor self-antigens and an NKT cell agonist to CD8aC DCs by
using a nanoparticle (NP)-based technology. We hypothesized
that this strategy might enhance DC/NKT cell/naive CD8C T
cell interactions, abrogate self-tolerance and thus promote
effective antitumor CTL responses. To this end, we targeted the
C-type lectin Clec9a (also known as DNGR1); this marker is
almost exclusively expressed by cross-priming DCs, and is
known to confer potent CTL responses.7,10,25 By using NPs dec-
orated with antibodies (Abs), we showed that simultaneous,
targeted delivery of a-GalCer and tumor self-antigens (Trp2
and gp100) to mouse CD8aC DCs via the Clec9a endocytic
pathway is instrumental in inducing a potent CTL response
that protects in prophylactic and therapeutic settings against
the development of aggressive tumors (melanoma). In the
human setting (with peripheral blood mononuclear cells
(PBMCs) from healthy donors and melanoma patients), co-
delivery of a-GalCer and a tumor antigen (Melan A) to
BDCA3C DCs strongly induced the expansion of tumor-anti-
gen-specific CD8C T cells in vitro. Our present findings may
have important implications for tumor immunotherapy and
vaccine development.
Results
Primary and secondary stimulation of NKT cells
is enhanced by targeting a-GalCer via NP/Clec9a
We first tested the ability of PLGA NPs containing a-GalCer
and OVA and decorated with anti-Clec9a Abs (see Table 1 for
information on the NPs’ physicochemical characteristics) to
activate NKT cells in vitro. NP/a-GalCer/OVA/Clec9a induced
greater cytokine production (including the production of IFN-
g, a critical antitumor cytokine) by spleen cells than the control
NP/a-GalCer/OVA/IgG and (albeit to a lesser extent) soluble,
non-targeted (free) a-GalCer (Fig. 1A, left panel and Fig. S1A).
Cytokine production was dependent on the antigen-presenting
molecule CD1d and on NKT cells (Fig. S1B). Furthermore,
cytokine production in response to NP/a-GalCer/OVA/Clec9a
was dependent on CD8aC DCs because spleen cells from
Baft3¡/¡ mice were much less able to produce IFN-g (Fig. 1A,
right panel). When pulsed in vitro with a-GalCer targeted via
NP/Clec9a, bone marrow-derived DCs induced higher levels of
IL-2 production by the NKT hybridoma DN32.D3 (Fig. 1B, left
panel and Fig. S1C for the phenotypic analysis of the DCs), rel-
ative to either non-targeted a-GalCer (NP/IgG) or free
a-GalCer. Treatment of DCs with anti-Clec9a Abs reduced
cytokine production by NKT cells in response to NP/a-GalCer/
OVA/Clec9a, but not NP/a-GalCer/OVA/IgG (Fig. 1B, right
panel). Hence, targeted delivery of a-GalCer via NP/Clec9a
effectively activated NKT cells in vitro.
We next evaluated the targeted a-GalCer’s ability to activate
NKT cells in vivo. Whatever the dose used for inoculation, NP/
a-GalCer/OVA/Clec9a induced a higher frequency of IFN-g
expressing NKT cells than NP/a-GalCer/OVA/IgG or non-tar-
geted a-GalCer plus OVA did (Fig. 1C, left panel and Fig. S2A).
It is noteworthy that the inoculation of 5 ng of a-GalCer incor-
porated into NP/Clec9a or 100 ng of non-targeted a-GalCer
resulted in similar proportions of IFN-g positive NKT cells.
Table 1. Physicochemical characterization of PLGA NPs containing a-GalCer and OVA or tumor peptides. PLGA NPs were characterized by dynamic light scattering and
zeta potential measurements. PLGA NPs size and zeta potential data represent the mean value § SD of 10 and 5 readings, respectively. The amount of encapsulated OVA
was determined by Coomassie dye protein assay (mean § SD, two independent experiments). The amount of encapsulated tumor antigens (gp100, Trp2, Melan A) was
determined by reversed-phase high-performance liquid chromatography. The incorporation of a-GalCer into NPs was total due to its hydrophobic nature. The amount of
Ab introduced into NPs was determined indirectly by Coomassie Protein Assay Reagent by measuring a small aliquot from the Ab solution at the starting point and at the

















0.5 21.0 – – 234.0 § 12.2 –17.3 § 1.5 27.9
NP(a-GalCer/OVA)-IgG 0.5 21.0 – – 221.0 § 10.4 –16.7 § 1.5 29.0
NP(a-GalCer/gp100/
Trp2)-Clec9A
0.5 – 42/38 – 220.6 § 12.5 –16.4 § 6.2 24.0
NP(a-GalCer/gp100/
Trp2)-IgG
0.5 – 42/38 – 208.6 § 10.6 –18.6 § 6.4 27.0
NP(a-GalCer/MelanA)-
CLEC9A
0.5 – – 48 234.8 § 10.9 –12.6 § 5.2 22.0
NP(a-GalCer/MelanA)-
IgG
0.5 – – 48 242.2 § 14.6 –14.4 § 5.1 23.0
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Figure 1. Primary and secondary stimulation of NKT cells is ameliorated by means of a-GalCer vectorization into NP/Clec9a. A, Left panel, Spleen cells from WT animals
were exposed to grading doses of free a-GalCer plus OVA or with a-GalCer plus OVA encapsulated into PLGA-based NPs armed with anti-Clec9a Abs (NP/a-GalCer/OVA/
Clec9a) or isotype control Abs (NP/a-GalCer/OVA/IgG). Right panel, Spleen cells from WT or Baft3¡/¡ were incubated with NP/a-GalCer/OVA/Clec9a or NP/a-GalCer/OVA/
IgG. Of note, Baft3 deficiency did not reduce the number of splenic NKT cells (not shown). B, BM-DCs were exposed for 2 hours to free or encapsulated a-GalCer and, after
washing, DCs were cultured with the NKT cell hybridoma DN32.D3. Right panel, Anti-Clec9a or IgG1 control was added (25 mg/ml) during the antigenic pulse. (A) and B,
IFN-g and IL-2 production was quantified 48 hours or 24 hours later by ELISA. Data represent a pool of 2 or 3 independent experiments. C, Left panel, Mice were i.v.
injected with PBS alone or graded doses of a-GalCer either in a free soluble form or encapsulated into NP/Clec9a or NP/IgG. After 3 hours, splenic NKT cells were screened
for intracellular IFN-g production. The average percentages of NKT cells positive for IFN-g are represented. D, Mice were i.v. injected with free a-GalCer (100ng/mouse) or
with a-GalCer encapsulated into NP/clec9a (5 ng/mouse). Seven days later, mice received a second injection of vectorized a-GalCer (NP/a-GalCer/OVA/Clec9a,
5 ng/mouse) and spleen NKT cells were screened for intracellular IFN-g production (left panel) and cell surface PD1 expression (right panel) 3 hours later. E, Left
panel, Representative dot plots of NKT cells expressing CCF4-blue fluorescence (corresponding to IL-10-b-lactamaseC cells). Right panel, the percentage of IL-10-
b-lactamaseC NKT cells among total NKT cells is represented (n D 5). C-E, Shown is a representative experiment of at least 3 (2 for panel D) performed (n D 5).
A-E, P < 0.01, P < 0.05 (a Kruskal–Wallis ANOVA).
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These 2 groups of animals did not differ in terms of the serum
IFN-g concentration and the extent of NK cell transactivation
(Fig. S2B and data not shown).
It is known that repeated stimulation with non-targeted
a-GalCer leads to NKT cell hyporesponsiveness as a result
of uncontrolled NKT cell activation.26 This hyporesponsive-
ness might have a profound impact on the development of
NKT cell-based vaccine therapies in cancer because it would
limit the prime-boost strategy. We therefore sought to
determine whether our delivery system could counter this
negative effect. To this end, mice were injected with 100 ng
of non-targeted a-GalCer or 5 ng of a-GalCer incorporated
into NP/Clec9a, which trigger similar levels of primary
NKT cell activation (Fig. 1C). As expected, inoculation of
non-targeted a-GalCer led to a much lower frequency of
IFN-g expressing NKT cells than in singly inoculated (NP/
a-GalCer/OVA/Clec9a) mice (Fig. 1D, left panel). Interest-
ingly, primary activation of NKT cells following administra-
tion of NP/a-GalCer/OVA/Clec9a resulted in a lower
degree of NKT cell hyporesponsiveness upon the second
challenge. Furthermore, this effect was associated with lower
cell surface expression of the hyporesponsiveness marker
programmed cell death protein-1 (PD-1) on NKT cells26
(Fig. 1D, right panel). Hence, primary activation of NKT
cells by NP/a-GalCer/OVA/Clec9a improves the functional-
ity (as measured by IFN-g production) of NKT cells upon
secondary restimulation. Inoculation of non-targeted
a-GalCer has also been shown to induce the expansion of
immunosuppressive, IL-10-producing NKT cells (NKT10
cells),27 which might also pose considerable problems for
vaccine-based cancer therapies. Our present study con-
firmed that the administration of non-targeted a-GalCer led
to the expansion of NKT10 cells (Fig. 1E). Remarkably, pri-
mary activation of NKT cells with NP/a-GalCer/OVA/
Clec9a dramatically reduced the proportion of NKT10 cells.
Together, primary and secondary stimulation of NKT cells
is enhanced by targeting a-GalCer via NP/Clec9a.
Co-delivery of particulate protein antigen and a-GalCer
via NP/Clec9a induces potent CTL and anti-tumor
responses
We next tested our synthetic delivery system’s efficacy with
regard to the in vivo expansion of CD8C T cells. To this
end, mice reconstituted with CFSE-labeled OVA257–264-spe-
cific CD8C T cells were subcutaneously inoculated with NP/
Clec9a containing both a-GalCer and OVA. Relative to
controls, NP/a-GalCer/OVA/Clec9a induced greater expan-
sion of OVA257–264-specific CD8
C T cells in the draining
lymph nodes and in the spleen (Fig. 2A, right panel,
Fig. S3A and S3B). Importantly, expansion of OVA-specific
CD8C T cells required the CD1d mode of antigen presenta-
tion because only baseline levels of proliferation were found
in Cd1d¡/¡ mice (Fig. 2A, left panel and Fig. S3B). This
finding suggests that help from NKT cells was critical for
Figure 2. Co-encapsulation of a-GalCer and OVA in NP/Clec9a induces potent CTL and anti-tumor responses. (A) (right panel), WT Mice, previously injected with CFSE-
labeled Rag2/OT-I cells, were s.c. inoculated with OVA (210 ng/mouse) and a-GalCer (5ng/mouse) either free or co-encapsulated in NP/IgG or NP/Clec9a. Three days later,
the proliferation of CFSE-labeled Va2 TCRC CD8aC in popliteal LNs was determined by flow cytometry (n D 5–7). Left panel, The same procedure was repeated but this
time WT and Cd1d¡/¡ mice were injected with NP/a-GalCer/OVA/Clec9a (nD 5). B, Six days after immunization, mice were transferred with CFSE-labeled SIINFEKL-primed
(syngeneic target cells) and PKH-26-labeled unprimed (syngeneic control cells) splenocytes. Data represent the percentage of specific lysis (n D 5). C, Free or vectorized
OVA (1.26 mg) and a-GalCer (30 ng) were injected s.c. in mice. Seven days later, mice were inoculated s.c. with OVA-expressing EG7 cells (2 £ 105 cells/mouse). D, Mice
previously reconstituted with Rag2/OT-I cells (5 £ 106 splenocytes/mouse) were inoculated with OVA-expressing EG7 cells. One and 5 d later, mice were injected with
free or vectorized OVA (210ng/mouse) plus a-GalCer (5ng/mouse). (C) and D, Tumor size was measured every 2 d (n D 8). A-D, One representative experiment out of at
least 2 is shown. P < 0.01, P < 0.05 (a Kruskal–Wallis ANOVA (A, left panel and B) and a Mann–Whitney U test ((A, right panel, C- D, area under curve).
e1339855-4 R. GHINNAGOW ET AL.
antigen cross presentation in our setting. Six days after
immunization, the level of OVA-specific T cell cytotoxicity
was measured in an in vivo assay. Inoculation of NP/
a-GalCer/OVA/Clec9a elicited a higher CTL response (as
assessed by target cell lysis) than in control animals
(Fig. 2B). To investigate the effects of targeted antigen and
a-GalCer on the control of tumor development, mice were
subcutaneously immunized with NP/a-GalCer/OVA/Clec9a
7 d before the engraftment of EL4 lymphoma cells
expressing OVA (EG7). As shown in Fig. 2C, inoculation of
NP/a-GalCer/OVA/Clec9a delayed the growth of EG7 lym-
phoma cells, relative to NP/a-GalCer/OVA/IgG and non-
targeted OVA plus a-GalCer. Moreover, NP/a-GalCer/
OVA/Clec9a vaccination of mice bearing pre-established
EG7 tumors resulted in a significant delay in tumor over-
growth (Fig. 2D). Taken as a whole, our results show that
OVA and a-GalCer targeted via NP/Clec9a have prophylac-
tic and therapeutic effects on solid tumor development.
Figure 3. Co-encapsulation of a-GalCer and tumor peptides in NP/Clec9a induces potent CTL and anti-tumor responses. A, Mice were s.c. inoculated at day 0, 7 and 14
with Trp2 and gp100 peptides (»2.4. mg each/mouse) and a-GalCer (30ng/mouse) either free or co-encapsulated in NP/IgG or NP/Clec9a. Three days later, skin-draining
LN cells were restimulated with a cocktail of Trp2 and gp100 (10 mg/ml). IFN-g was measured 48 hours later. Shown is a representative experiment of 2 performed (n D
5). B, Mice were injected at day 0 and day 7 with peptides (»2.4. mg each/mouse) and a-GalCer (30ng/mouse) either free or co-encapsulated in NP/IgG or NP/Clec9a.
Seven days later, mice were inoculated with B16F10 (5 £ 105 cells/mouse). C, Mice were s.c. implanted with B16F10. Five (tumor volume: 25–50 mm3) and 12 d later,
mice were injected with free or vectorized peptides (»2.4. mg each/mouse) and a-GalCer (30ng/mouse). (B) and C, Tumor volume was measured every 2 d (n D 16, 2
pooled experiments). D, The same therapeutic protocol (as that described in panel C) was performed. Left panel, To investigate the role of NKT cells in protection, Ja18¡/
¡ mice were vaccinated with NP/a-GalCer/tumor peptides/Clec9a. Right panel, Vaccinated wild type (NKT cell-competent) mice were treated with an anti-CD4 depleting
Ab or an isotype control 2 d before the first immunization (day 3 post B16 inoculation) and 2 d before the boost (day 10 post B16 inoculation). E, Vaccinated mice were
treated with an anti-CD8b depleting Ab or an isotype control (days 7, 10, 13 and 16). (D) and E, Tumor volumes are indicated at day 15 post-B16 implantation (n D 8). F,
On day 14, the tumor mass of each mouse was excised and the frequency of Trp2-specific CD8C T cells and perforin-expressing CD8C T cells were determined by flow cytome-
try (2 pooled independent experiments). P < 0.01, P < 0.05 (a Kruskal–Wallis ANOVA ((A)and F) and a Mann–Whitney U test (B-E) (area under curve for panel C).
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NPs incorporating a-GalCer and self-tumor antigens
protect against tumor development
We next looked at whether our delivery system could abrogate
the tolerance of self-tumor antigens. To this end, 2 tumor pep-
tides (corresponding to dominant CD8C T-cell epitopes from
the highly malignant B16 melanoma antigens Trp2 and gp100,
respectively) were incorporated into NP/a-GalCer/Clec9a
(Table 1). Relative to control groups, the subcutaneous immu-
nization of mice with NP/a-GalCer/tumor peptides/Clec9a
resulted in greater IFN-g production by draining lymph nodes
and spleen cells upon peptide restimulation (Fig. 3A and
Fig. S4A). The growth of B16F10 cells was considerably delayed
(relative to control groups) in mice having been prophylacti-
cally vaccinated with NP/a-GalCer/tumor peptides/Clec9a
(Fig. 3B). We next investigated the constructs’ potential thera-
peutic effects on previously implanted tumors. Inoculation of
NP/a-GalCer/tumor peptides/Clec9a in tumor-bearing mice
was found to strongly delay tumor progression (Fig. 3C).
Experiments with Ja18¡/¡ mice were then used to establish
whether the protective effect of the NP-based vaccine required
help from NKT cells. Indeed, the delay in tumor outgrowth
clearly required the presence of NKT cells (Fig. 3D, left panel).
On the other hand, depletion of CD4C T cells had no effect on
vaccine efficacy (Fig. 3D, right panel and Fig. S4B). Of note, the
anti-CD4 Ab also depleted CD4C NKT cells (Fig. S4B) indicat-
ing that, in our setting, the help from CD4¡ NKT cells is suffi-
cient to delay the tumor growth. To prove that the protective
effects of the vaccine depended on CTLs, CD8C T cells were
depleted by treatment with an anti-CD8b Ab (Fig. S4C). This
procedure indeed abrogated the vaccine’s antitumor effect
(Fig. 3E). Hence, the therapeutic effect triggered by the vaccine
depended on NKT cells (but not T-helper cells) and CD8C T
cells. We next quantified the intratumoral infiltration of CD8C
T cells. The frequency and cell number of Trp2-specific CD8C
T cells (as well as perforin-expressing CD8C T cells) was higher
Figure 4. NP/CLEC9A target BDCA3C DCs to activate human NKT cells. A, Live HLA-DRC cells were analyzed to determine the percentage of DC subsets, including BDCA3C
DCs. B, BDCA3CCD11clow (population A) BDCA3¡CD11cmed (population B) and BDCA3¡CD11chi (population C) were analyzed for the expression of CLEC9A. C, 1 £ 105 DCs
were incubated with 25 or 100 mg of NP/IgG/AF647 or NP/CLEC9A/AF647 for 15 min. The percentage of AlexaFluor647-positive cells were analyzed by flow cytometry (left
panel). Specificity of the targeting in BDCA3CCD11clow DCs is shown (right panel). The experiment shown is representative of 3 donors. (D) and E, 1£ 104 DCs were pulsed
with graded doses of free or vectorised a-GalCer and were then co-cultured with 5 £ 104 NKT hybridoma 55ab (D) or with primary NKT cells (E). Mouse IL-2 and human
IFN-g were measured in the supernatant by ELISA after 24 hours and 48 hours respectively (pool of 3 donors). P < 0.05 (a Kruskal–Wallis ANOVA).
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in vaccinated, protected animals than in control groups (Fig. 3F
and Fig. S4D, left panel and not shown). Of interest, a clear
inverse correlate between the percentage of intratumoral per-
forin-expressing CD8C T cells and tumor size was observed
(Fig. S4E). The intratumor ratio of tumor antigen-specific
CD8C T cells to regulatory T cells represents an index closely
correlated with tumor regression,28 The intratumor ratio of
Trp2-specific CD8C T cells (and perforin-expressing CD8C T
cells) to Foxp3-expressing CD4C CD25C cells was also higher
in animals vaccinated with NP/a-GalCer/tumor peptides/
Clec9a (Fig. S4D, right panel). Taken as a whole, our results
show that the incorporation of tumor self-antigens and
a-GalCer into an NP/Clec9a vector promotes a potent, mela-
noma-self-antigen-specific CD8C T cell response and has pro-
phylactic and therapeutic effects on the growth of tumor cells.
NP/a-GalCer/CLEC9A targets BDCA3C DCs and optimizes
human NKT cell activation
We next investigated NP/CLEC9A’s ability to effectively target
human BDCA3C (CD141C) DCs. In functional terms, this sub-
set resembles murine CD8aC cross-presenting DCs and thus
constitutes a very interesting target for cancer immunother-
apy.5,6,29 To this end, human DCs were differentiated and
expanded in vitro from cord blood haematopoietic progenitor
cells. Several subpopulations of DCs (including CD11clow
BDCA3C, accounting for around 35% of total DCs, CD11cmed
BDCA3¡ and CD11chi BDCA3¡ subpopulations) were
obtained at the end of the differentiation procedure (Fig. 4A).
Flow cytometry analysis indicated that the CD11clow BDCA3C
DC subpopulations was the only one to express CLEC9A
(Fig. 4B). To further establish whether or not the NP formula-
tion (Table 1) targets BDCA3C DCs, the DCs were incubated
with AF647-labeled NPs. As shown in Fig. 4C, incubation of
human DCs with NP/CLEC9A revealed that BDCA3C DCs
were specifically targeted. In contrast, DCs incorporated low
levels of NP/IgG. In co-culture experiments, in vitro-generated
DCs pulsed with graded doses of NP/a-GalCer/CLEC9A
induced a higher level of cytokine production by NKT cells
than control preparations did. Indeed, the mouse NKT cell
hybridoma 55ab (which expresses a human invariant Va24/
Vb11 T cell receptor that binds to the a-GalCer presented by
human CD1d) produced a greater amount of IL-2 (Fig. 4D).
Similarly, primary NKT cells released greater amounts of IFN-
g when incubated with DCs exposed to NP/a-GalCer/CLEC9A
(Fig. 4E). In contrast, human primary NKT cells produced very
little IL-4 and no IL-17A (not shown). In summary, targeting
a-GalCer to human BDCA3C CLEC9AC DCs results in a
strong NKT cell response.
NP/a-GalCer/CLEC9A containing the tumor antigen Melan
A strongly promotes the expansion of Melan-A-specific
CD8C T lymphocytes
Ex vivo or in vivo expansion of tumor-antigen-specific CD8C T
lymphocytes is an important objective in cancer immunother-
apy. To probe the potential impact of targeting BDCA3C DCs
on the in vitro priming of CD8C T cells, PBMCs from healthy
HLA-A2C donors were cultured with a-GalCer and an
antigenic peptide from Melan A (a major target for anti-mela-
noma therapies). HLA-A2C donors were chosen because they
have na€ıve precursors that are specific for the HLA-A2-
restricted Melan A epitope ELAGIGILTV26–35. For some
donors, a-GalCer and Melan A18–35 encapsulated in NP/
CLEC9A strongly promoted the expansion of Melan A-specific
CD8C T cells, relative to other groups (Fig. 5A and Fig. S5A).
Although the level of response varied from one donor to
another, the relative overall increase in expansion was statisti-
cally significant (Fig. 5B and data not shown). At day 14 post-
priming, most Melan-A-specific CD8C T cells displayed an
effector memory phenotype (CD45RA¡ CCR7¡) (Fig. S5B).
The effect of CLEC9A Ab-armed NPs on the expansion of
Melan A-specific CD8C T cells was next tested using PBMCs
from melanoma patients. Since the abnormally low frequency
of circulating NKT cells in cancer patients is a major hurdle in
NKT-cell-based anti-tumor therapy,30,31 we considered that it
was important to test NP/a-GalCer/Melan A/CLEC9A’s effect
on NKT cell expansion. In agreement with the literature data,
the melanoma patients had a lower NKT cell count (but
enhanced, albeit not significant, BDCA3C DC count, Fig. S5C)
than healthy donors on day 0 (Fig. 5C). However, after 14 d of
culture, NKT cells from melanoma patients expanded strongly
in response to NP/a-GalCer/Melan A/CLEC9A. It is notewor-
thy that the fold increase in the frequency of NKT cells from
melanoma patients was greater than for healthy donors; how-
ever, the difference was not statistically significant. We next
investigated NP/a-GalCer/Melan A/CLEC9A’s ability to
expand CD8C T lymphocytes from melanoma patients. The
formulation strongly induced the expansion of Melan A-spe-
cific CD8C T cells (Fig. 5D). The proportion of Melan A-spe-
cific CD8C T cells was higher in melanoma patients than in
healthy donors (»19.5% and »6.3%, respectively) (Fig. 5B).
Importantly, expanded Melan A-specific CD8C T cells pro-
duced IFN-g and CD107 (a degranulation marker) in response
to restimulation with Melan A peptide but not with an irrele-
vant peptide (Fig. 5E and Fig. S5D). In summary, NPs deco-
rated with anti-CLEC9A Abs strongly induced the expansion
of NKT cells and tumor antigen-specific CD8C T cells in
healthy donors and in melanoma patients; this augurs well for
the potential use of our vaccine formulation in cancer patients.
Discussion
Results from preclinical and clinical studies have highlighted
the value of using the NKT cell agonist a-GalCer in cancer
treatments.32,33 In the clinic, a-GalCer has been inoculated
alone as a soluble agent or loaded onto PBMCs or DCs.34,35
Although animal studies have clearly revealed that the adju-
vant functions of NKT cells can be exploited by the co-admin-
istration of soluble a-GalCer and antigens,19,22,36 the NKT
cells’ helper functions have yet to be tested in a human set-
ting. In the mouse system, there is evidence to suggest that
NKT cells can license DCs for cross-priming; the resulting
CTL response may differ from that generated by DCs licensed
by TLR activation or by T-helper lymphocytes.22,21,23,24,37
Importantly, Semmling and al. demonstrated that the CD1d-
restricted lipid and protein antigens (free a-GalCer and
OVA) must be presented by the same DC.24 To generate an
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effective CTL and antitumor response, we exploited the NKT
cells’ unique ability to license cross-priming DCs. To this end,
we developed a targeted strategy based on the use of PLGA
NPs decorated with anti-clec9a Abs. This formulation was
designed to simultaneously deliver tumor antigens and
a-GalCer to the same cross-priming DCs, giving a cognate
interaction. The biodegradable polymer PLGA has been
widely used for drug delivery in general and in cancer therapy
in particular. PLGA NP systems have several advantages,
including (i) a high antigen density, (ii) the ability to incorpo-
rate various classes of molecules (including proteins and lip-
ids), (iii) the ability to reach MHC I pathway after uptake by
Figure 5. Co-encapsulation of a-GalCer and Melan A in NP/CLEC9A augments the proliferation of Melan A-specific CD8C T cells in vitro. A, PBMCs from HLA-A2C donors
were cultured with Melan A peptide alone (0.9 mg/ml) or supplemented with a-GalCer (10ng/ml), either free or encapsulated in NP/Clec9a or NP/IgG. Fourteen days later,
the proportion of Melan A-specific (dextramer A2/Melan A26–35-specific cells, Dex/M
C) CD8C T cells were determined by flow cytometry. Data from 3 donors are shown. B,
The magnitude (frequency and cell number/well) of the Melan A-specific CD8C T cell populations from a pool of 7 healthy donors is shown. Horizontal bars indicate mean
values. C, At the end of the culture, gated CD3C expanded cells were analyzed for 6B11 labeling. The frequency of human NKT cells (CD3C 6B11C) from healthy donors
and from melanoma patients is shown at day 0 and day 14. The fold expansion of NKT cells is presented in the right panel. (D) and E, PBMCs from melanoma donors were
cultured with NP/a-GalCer/Melan A/Clec9a. D, Proportions of Melan A-specific CD8C T cells are shown at day 0 and day 14. E, The proportion of Melan A-specific CD8C T
cells (day 14) expressing IFN-g or CD107 upon activation with T2 cells pulsed with the Melan A peptide or with an irrelevant peptide is shown. P < 0.001, P < 0.01,
P < 0.05 (a Wilcoxon test (B, right panel), a Mann–Whitney U test (C, (D) and E) or a Kruskal–Wallis ANOVA (B, left panel)).
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DCs, and (iv) slow release kinetics.38 By using PLGA NPs
armed with anti-clec9a Abs, we clearly demonstrated that
active co-delivery of tumor antigens and a-GalCer to cross-
priming DCs promotes better CTL and antitumor responses
than free antigen and a-GalCer do. These data extend our
previous findings in experiments with DEC205 (a marker that
is not exclusively expressed by cross-priming DCs) and the
non-self-antigen OVA.9 After checking that our NP-based
anti-Clec9a formulation also triggered cross-priming of OVA
and protected against the growth of aggressive, OVA-express-
ing EG7 tumors, we then showed that it can abrogate the
immune tolerance of tumor self-antigens (Trp2, gp100). The
resulting potent antitumor CTL response was able to prophy-
lactically and therapeutically control solid tumor outgrowth
in a model of aggressive melanoma. We showed that antigen
cross-presentation in vivo has an absolutely requirement for
help from NKT cells, but not from conventional T-helper
cells. With the abrogation of tolerance, our data extend
Semmling et al.’s pioneering work and shed light on novel
therapeutic approaches for controlling tumor development.
With a view to optimizing immune responses (especially
in the context of cancer), vaccination usually involves several
prime-boost immunizations. Our NP formulation’s ability to
promote strong CTL and antitumor responses (relative to
free tumor antigens and a-GalCer) may be rooted in the
priming and boost steps. Firstly, the NKT cells’ primary acti-
vation threshold (i.e. the IFN-g production) is higher follow-
ing direct activation by cross-priming DCs. As a result, the
enhancement of the NKT cells’ helper function is likely to
prime na€ıve CTLs to a greater extent. Secondly, the cross-
talk between DCs, NKT cells and na€ıve CD8C T cells elicited
by our co-delivery system is likely to lead to a CTL response
that differs both quantitatively and qualitatively from that
induced by more classical activation pathways (e.g., DCs
matured with TLR agonists or licensed by T-helper cells).
Interestingly, D€olen and colleagues observed that the co-
encapsulation of antigen (OVA) and a-GalCer in NPs trig-
gers stronger CTL and antitumor responses than co-encap-
sulation of antigen and a TLR agonist does.37 Although the
latter researchers did not specifically target DCs, their results
suggested that cognate licensing of DCs by NKT cells is
more effective than conventional, TLR-based adjuvants. Sev-
eral lines of research indicates that a-GalCer and TLR ago-
nists can act cooperatively to promote DC maturation and T
cell priming.19,39-41 In the future, we intend to look at
whether or not the incorporation of a-GalCer and a TLR
ligand in our NP-based formulation will cooperatively
enhance the licensing of DCs and improve the outcome of
antitumor vaccination. Thirdly, our data clearly show that
the use of our NP formulation was associated with stronger
secondary stimulation of NKT cells (IFN-g production) and
a greater ability to boost CTLs. The [cross-priming] DCs’
unique ability to limit the appearance of unresponsive (PD1-
expressing) NKT cells has positive implications for the devel-
opment of NKT cell-based cancer therapies. Fourthly, our
formulation strongly limited the expansion of IL-10-express-
ing NKT cells. A recent study showed that mice pretreated
with a-GalCer are less able to reject tumors (due to the role
of NKT10 cells).27 Therefore, the reduced expansion of
NKT10 seen in mice vaccinated with anti-Clec9a Ab-bearing
NPs might contribute to the observed antitumor effects.
Overall, there are many reasons for co-delivering protein
antigen and a-GalCer to cross-priming DCs. In view of the
promising proof-of-concept results, we considered that it
was important to analyze the co-delivery strategy’s potential
added value in a human setting.
Given that the NKT/CD1d axis is conserved in humans
(with no HLA restriction), NKT cell therapy has attracted
interest. Adoptive transfer of in-vitro-expanded, tumor-spe-
cific CD8C T cells is an interesting immunotherapeutic
option. Hence, the NKT cells’ licensing function might be
worth exploiting (either alone or in combination with vaccine
strategies) in cell-based allogeneic immunotherapy. Targeting
antigens to human BDCA3C DCs via the CLEC9A endocytic
pathway favors antigen cross-presentation and the priming of
CD8C T cell responses.25 To assess the targeting properties of
anti-CLEC9A Ab-armed NPs, we studied DCs expanded
from cord blood haematopoietic progenitor cells. Under our
experimental conditions, the ex vivo generated DCs resem-
bled blood DCs.42 The NP formulation (i) specifically targets
cross-priming, CLEC9A-expressing DCs, and (ii) triggers a
strong NKT cell response. Targeted a-GalCer not only
improves the in vitro expansion of human NKT cells (data
not shown) but also enhances their cytokine response relative
to experiments with free a-GalCer or control NPs. Finally,
using the clinically relevant tumor antigen Melan A, we show
that NKT cell-licensed human DCs trigger the expansion of
functional Melan A-specific CD8C T cells both in healthy
donors and - more importantly - in melanoma patients. To
the best of our knowledge, our study is the first to have
implemented Semmling et al.’s concept in a human system.
An in vivo demonstration will require the use of humanized
mice. Relative to cancer-free individuals, melanoma patients
have lower NKT cell counts and/or impaired NKT cell func-
tions.30,31 We showed that targeted a-GalCer strongly
expands NKT cells from melanoma patients. Taken as a
whole, our results suggest that this NP-based formulation
may have promise in the treatment of cancer. One concern
with the clinical implementing of this type of vaccine is the
relatively low NKT cell count in humans (relative to mice).
Various means of circumventing this potential drawback are
being developed, and the transfer of autologous, ex-vivo-
expanded NKT cells appears to be a reliable strategy for
enhancing anticancer strategies based on NKT cells.43 More-
over, the reprogramming of NKT cells to induced, pluripo-
tent stem cells and their subsequent re-differentiation into
more functional NKT cells (compared with the parental cells)
is opening up new avenues in this field.44,45
In conclusion, we have developed an experimental strategy
that emulates NKT cell help and analyze the corresponding for-
mulation’s effect on the expansion of tumor antigen CD8C T
cells (in mouse and human systems) and the control of tumor
development. With regard to improving vaccine-based cancer
treatments, our data highlight the potential benefits of deliver-
ing tumor antigens and a-GalCer into cross-presenting DCs.
The present preclinical results constitute the first proof of con-





Male C57BL/6 mice (8-week old) were purchased from Janv-
ier (France). Rag2/OT-I transgenic mice (enriched in
OVA257–264-specific CD8
C T cells) were from Jackson Labora-
tory (France). The generation of Cd1d¡/¡, Ja18¡/¡ (which
lacks NKT cells) and Baft3¡/¡(which have a strongly reduced
proportion of CD8aC DCs) mice was described in.46-48 The
IL-10-b-lactamase reporter mouse (the ITIB mouse) was
described in.49 All animal work conformed with the Lille Pas-
teur Institute’s regulations on animal care and use guidelines
and was approved by the local Animal Care Committee
(CEAA75 and 00357.03).
Reagents and peptides
a-GalCer was synthesized as described.9 OVA was pur-
chased from InvoGen (France), vybrant CFDA SE Cell
Tracer Kit from Invitrogen (France) and the PKH26 Red
Fluorescent Cell Linker Kit from Sigma Aldrich (France).
All cytokines for expansion and differentiation assays were
from Peprotech (France). The following peptides were syn-
thesized to a purity >95–99% by high-performance liquid
chromatography (GL Biochem, China): SIINFEKL, spanning
amino acids 257–264 of the mouse OVA; SVYDFFVWL,
spanning amino acids 180–188 of the mouse melanoma
antigen tyrosinase related protein-2 (Trp2); KVPRNQDWL,
spanning amino acids 25–33 of the human melanoma gly-
coprotein 100 (gp100) and HSYTTAEELAGIGILTV, span-
ning amino acids 18–35 of the human Melan A.
Description of Abs, tetramers and dextramers
Allophycocyanin-conjugated mAbs against mouse Siglec H, PE-
Cy7 conjugated CD11c, anti-NK1.1, anti-PD1, anti Va2-TCR,
FITC-conjugated anti-TCRb, anti-CD8a, CD172a, PerCp-
CY5.5-conjugated CD24, Alexa Fluor647-conjugated IFN-g and
isotype control, Pacific blue-conjugated I-A/I-E, PE-conjugated
anti-CD8a, anti-Clec9a (also termed DNGR-1) were all pur-
chased from BD Biosciences (France) or Ozyme/Biolegend
(France). Antibodies used to analyze CD45C-enriched tumor
cells were as follows: CD3-APCCy7, CD8-Alexa Fluor 700, CD4-
Pacific blue, CD25-FITC, FoxP3-PeCy7, perforin-APC (Biole-
gend or eBiosciences). Mouse anti-human Abs were as follows:
APCCy7-conjugated HLA-DR, AF700-conjugated CD11c and
PercpCy5.5 anti-NKT (clone 6B11), FITC anti-human Lineage
Cocktail were from Biolegend. V500-conjugated CD8, AF700-
conjugated CD3, AF647-conjugated CCR7, FITC-conjugated
CD3, V450-conjugated (CD3, CD14, CD19, CD20, CD56),
FITC-conjugated IFN-g, APC-H7-conjugated CD3, V421-conju-
gated HLA-DR, PECy7-conjugated CD45RA and FITC-conju-
gated CCR7 were all purchased from BD Biosciences. APC-
conjugated BDCA1, PE-conjugated CLEC9A, FITC-conjugated
BDCA3 and PE-conjugated anti-NKT (clone 6B11), APC-conju-
gated BDCA3 were from Miltenyi Biotec (France). PE-conju-
gated dextramer H-2Kb/Trp2180–188 and dextramer A2/Melan
A26–35 were from Immudex (Denmark). PE-conjugated
a-GalCer-loaded CD1d tetramer was from the National Institute
of Allergy and Infectious Diseases Tetramer Facility. Flow cyto-
metric analyses were performed with a Fortessa cytometer (BD
Biosciences) and the acquired data were processed using FlowJo
software (Tree Star Inc.). Pure anti-mouse Clec9a (clone 7H11),
anti-human CLEC9A (clone 8F9) and isotype rat IgG1 (clone
HRPN) and mouse IgG2a (clone C1.18.4) used for the NP for-
mulation were from Miltenyi Biotec and from Bio X Cell (USA),
respectively. The neutralizing rat anti-mouse CD8b Ab (YTS-
156.7, IgG2b) was described in50 and the anti-mouse CD4 Ab
(GK1.5, IgG2b) was from Dr L. Fend (Transgene, France). The
isotype controls were from Bio X Cell.
Preparation and characterization of PLGA-based NPs
Poly(lactic-co-glycolic acid) (PLGA)-based NPs coated with lipid-
polyethylene glycol and carrying Abs were generated using the
copolymer PLGA essentially as described.9,51,52,44 In brief, endo-
toxin-free full OVA (5 mg) or tumor peptides (20 mg) and
a-GalCer (50 mg) were co-encapsulated to 100 mg of PLGA.
Mouse or human anti-Clec9A/CLEC9A Abs or their isotype con-
trols were attached to the lipid-polyethylene glycol layer.9,51,52
PLGA-based NPs were characterized by dynamic light scattering
and zeta potential (see details in Table 1).9,51 Incorporation of
OVA or peptides in NPs was quantified by Coomassie dye protein
assay (Thermo Fischer scientific, USA) or by reversed-phase high-
performance liquid chromatography.53 The presence of Abs on
the particle surface was quantified by Coomassie dye protein assay.
Cell lines and mouse hybridomas
EG7 and B16F10 cells were obtained from the American type
culture collection. The Va14/Vb8.2C NKT cell hybridoma
DN32.D3 was from A. Bendelac (USA). The mouse T cells
hybridoma 55a/b cells transfected with a human invariant
Va24/Vb11 TCR (which recognizes a-GalCer presented by
human CD1d) was described by Thedrez and colleagues.54
In vitro validation of the NPs
Spleen cells were incubated with grading doses of free or encap-
sulated a-GalCer plus OVA for 48 hours. Bone marrow-
derived DCs (BM-DCs) generated in the presence of fms-like
tyrosine kinase 3 ligand were incubated during 2 hours with
free or vectorized a-GalCer (1 £ 105/well) in the presence or
absence of anti-Clec9a or anti-IgG1 (25mg/ml). After washes,
NKT hybridoma (DN32.D3, 1 £ 105 cells/well) were added to
pulsed BM-DCs for 24 hours.
Assessment of primary and secondary NKT cell activation
in vivo
Mice were administrated intravenously (i.v.) with different
doses of free or vectorized a-GalCer. Three hours later, sera
were collected for IFN-g quantification and spleen cells were
assessed for IFN-g intracellular staining by flow cytometry. To
study NKT cell hyporesponsiveness, mice received a second
challenge of vectorized a-GalCer (NP/a-GalCer/OVA/Clec9a)
7 d after the primo-activation. To quantify the frequency of IL-
10-producing NKT cells, ITIB (IL-10-reporter) mice were i.v
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administrated with free or vectorized a-GalCer and one month
later the expression of b-lactamase (IL-10) by NKT cells was
assessed by flow cytometry.49 Briefly, spleen cells were resus-
pended in PBS containing CCF4-AM substrate (1 mM) supple-
mented with probenecid (2.5 mM), and then incubated in the
dark for 45 min at room temperature. The cells were then
washed, labeled with appropriate Abs, a-GalCer-loaded CD1d
tetramer and propidium iodide and analyzed by flow
cytometry.
Analysis of the CD8C T cell and anti-tumor response
to OVA or OVA-expressing tumor cells
To assess the in vivo OVA-specific CD8C T cell response,
CFSE-labeled Rag2/OT-I spleen cells (2 £ 107) were adoptively
transferred (i.v.) to na€ıve C57BL/6 mice at day 0. One day later,
mice were immunized into the footpads with free or vectorized
OVA plus a-GalCer (200 ng OVA and 5ng a-GalCer/mouse).
The frequency of CFSE-labeled OVA-specific CD8C T cells
were analyzed in popliteal lymph nodes (LNs) and spleen cells
at day 4 by flow cytometry. To this end, cells were stained with
anti-CD8-PE and anti-TCRVa2-PECy7 Abs. For the in vivo
CTL assay, 6 d after immunization with NPs, mice were i.v
injected with both CFSE-labeled SIINFEKL-pulsed splenocytes
and PKH-26-labeled non pulsed splenocytes (2 £ 107 cells/
mouse). Two days later, spleen cells were harvested and the
number of CFSE-labeled and PKH-26-labeled cells were deter-
mined by flow cytometry. The percentage of specific lysis was
calculated as follows: (1-{ratio non pulsed/ratio pulsed}) X 100,
where the ratio is equal to number of PKH-26-labeled cells/
CFSE-labeled cells. Mice were s.c. injected with free or vector-
ized OVA and a-GalCer. Seven days later, mice received s.c.
OVA-expressing EL-4 lymphoma cells (EG7 cells, 2 £ 105
cells/mouse). In the therapeutic context, mice were first recon-
stituted (i.v.) with Rag2/OT-I cells (5 £ 106 spleen cells/mouse)
and then inoculated with EG7 cells. Mice were immunized with
free or vectorized OVA and a-GalCer 1 day and 5 d after the
inoculation of EG7 cells. Tumor volume (mm3) was calculated
using the formula: length (mm) X (width2 (mm2) X 3.14/6. For
ethical reasons, mice were sacrified before tumor size reached
1500 mm3.
Analysis of the CD8C T cell response to self-antigens
and assessment of anti-tumor responses
To analyze the immune response to tumor self-antigens, the for-
mulations were injected subcutaneously (s.c.) in the back of the
mouse 3 times with an interval of 7d. Three days after the last
injection, cytokine production by skin-draining lymph node
(LN) cells and/or splenocytes was quantified after restimulation
with Trp2 and gp100 peptides (10mg/ml). To study the effect of
the vaccine on the anti-tumor response, mice were injected twice
(day 0 and day 7) and were implanted with 5 £ 105 B16F10 cells
at day 14. For the therapeutic setting, mice were injected with 5
£ 105 B16F10 cells (day 0) before the 2 immunizations (day 5
and day 12). Tumor size was measured using a caliper every 2 d.
Infiltration of T cells in tumors was analyzed at day 14 (thera-
peutic protocol). Briefly, single cell suspensions from tumors
were enriched for CD45C cells using the multiMACS separation
system (Miltenyi Biotec). Cells were stained with the PE-conju-
gated dextramer H-2Kb/Trp2180–188 at RT for 30 min and then
surface stained for CD3 and CD8. For regulatory CD4C T cell
labeling, tumor cells were surface stained for CD3, CD4 and
CD25 and fixed, permeabilized and labeled with anti-Foxp3 Ab.
Generation of BDCA-3C CLEC9AC DCs and NKT cells
Cord blood haematopoietic progenitor CD34C cells were from
ABCell-Bio (Paris, France) or from the EFS Grenoble. To
amplify haematopoietic progenitor cells, cells were cultured in
the stemspan medium in the presence of fms-like tyrosine
kinase 3 ligand (100ng/ml), stem cell factor (100ng/ml), IL-3
(20ng/ml) and thrombopoietin (50ng/ml) for one week. To
induce differentiation of the expanded cells into DCs, cells
were cultured in complete RPMI 1640 medium (round-bottom
96 well plate, 1–2 £ 104 cells/well) containing stem cell factor
(20ng/ml), granulocyte-macrophage colony-stimulating factor
(20ng/ml), IL-4 (20ng/ml) and fms-like tyrosine kinase 3 ligand
(100ng/ml). To optimize the differentiation step and to increase
the yield of DCs, 1mM stemregenin-1 (Calbiochem, France)
was added.42 The milieu plus differentiation factors were
renewed after 5 d. Dendritic cells were harvested between day
10 and day 14. NKT cells were expanded from human PBMCs.
Briefly, free or vectorized a-GalCer (10ng/ml) was added at day
0 and IL-2 (50ng/ml) at day 1. At day 7, the percentage of NKT
cells (CD3C 6B11C cells) was determined by flow cytometry.
To enrich NKT cells, cells positive for 6B11 (a mAb that recog-
nizes a unique determinant in the CDR3 region of the invariant
(Va24-JaQ) TCR chain of NKT cells) were selected with
immune-magnetic beads according to the manufacturer’s
instructions (MACS separator, Miltenyi Biotec).
Targeting of BDCA-3C CLEC9AC DCs and co-cultures
with NKT cells
To study the specificity of the targeting, total DCs (1 £ 105
cells/well) were incubated with Alexa Fluor647-labeled NPs.
After 15 minutes, the frequency of Alexa Fluor647 positive cells
was analyzed within the different DC subpopulations by flow
cytometry. To study NKT cell activation, total DCs were pulsed
with free or vectorized a-GalCer and co-cultured for 24 or
48 hours with NKT hybridoma or with primary NKT cells
(purity >95%) (ratio 1:5).
Origin of PBMCs
Blood samples from healthy donors and from melanoma
patients (stage I to IV) were obtained from the EFS Grenoble.
Approval to conduct the study was given by the local ethics
committee of Grenoble University Hospital. The procedures
are in accordance with the Helsinki Declaration of 1975 and all
participants gave their written consent. PBMC samples were
obtained via standard protocols.
Expansion of Melan A26–35-specific CD8
C T cells
To expand Melan A26–35-specific CD8
C T cells, PBMCs (2 £
106 cells/well) from HLA-A2C individuals were cultured with
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free or vectorized Melan A18–35 peptide (0.9mg/ml) plus
a-GalCer (10ng/ml) in the presence of IL-2 (50ng/ml) for 14 d.
Dextramer A2/Melan A26–35-specific cells were analyzed by flow
cytometry. To analyze IFN-g and CD107 expression, cells were
first labeled with PE-conjugated dextramer A2/Melan A26–35
washed and restimulated with Melan A peptide-pulsed TAP-
deficient T2 cells (10:1 ratio) for 5 hours. Cells were then sur-
face-labeled with anti-CD3 and anti-CD8 Abs and submitted to
IFN-g intracellular staining. For CD107 detection, anti-
CD107aCb Abs were added in the medium at the beginning of
the restimulation in the presence of Golgi-STOP for 4 hours.
Cells were then labeled with anti-CD3 and anti-CD8 Abs.
Statistical analysis
Data are expressed as the mean § SEM. A Mann-Whitney U test
was used to compare 2 groups, unless otherwise specified. Compar-
isons of more than 2 groups with each other were analyzed by one-
way analysis of variance (ANOVA) Kruskal-Wallis test (nonpara-
metric), followed by Dunn’s post-test (PRISM v6 software; Graph-
pad). For tumor size, means of “area under the curve” of each
individual were compared using a Mann–Whitney U test unless
otherwise specified. A P value<0.05 was considered significant.
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